ABSTRACT

Introduction

Understanding the pathogenesis and risk factors to control the coronavirus disease 2019 (COVID-19) is necessary. Due to the importance of the inflammatory pathways in the pathogenesis of COVID-19 patients, evaluating the effects of anti-inflammatory medications is important. Glucagon-like peptide 1 receptor agonist (GLP-1 RA) is awell-known glucose-lowering agent with anti-inflammatory effects.

Areas covered

Resources were extracted from the PubMed database, using keywords such as glucagon-like peptide-1, GLP-1 RA, SARS-CoV-2, COVID-19, inflammation, in April2021. In this review, the effects of GLP-1RA in reducing inflammation and modifying risk factors of COVID-19 severe complications are discussed. However, GLP-1 is degraded by DPP-4 with aplasma half-life of about 2–5 minutes, which makes it difficult to measure GLP-1 plasma level in clinical settings.

Expert opinion

Since no definitive treatment is available for COVID-19 so far, determining promising targets to design and/or repurpose effective medications is necessary.

中文翻译：

---

GLP-1 在 COVID-19 患者中的抗炎作用

摘要

介绍

有必要了解控制 2019 年冠状病毒病 (COVID-19) 的发病机制和风险因素。由于炎症通路在 COVID-19 患者发病机制中的重要性，因此评估抗炎药物的作用很重要。胰高血糖素样肽 1 受体激动剂 (GLP-1 RA) 是众所周知的具有抗炎作用的降糖剂。

涵盖的领域

2021 年 4 月，使用胰高血糖素样肽 1、GLP-1 RA、SARS-CoV-2、COVID-19、炎症等关键字从 PubMed 数据库中提取资源。在这篇综述中，讨论了 GLP-1RA 在减少炎症和改变 COVID-19 严重并发症的危险因素方面的作用。然而，GLP-1 被 DPP-4 降解，血浆半衰期约为 2-5 分钟，这使得在临床环境中难以测量 GLP-1 血浆水平。

专家意见

由于到目前为止还没有针对 COVID-19 的明确治疗方法，因此有必要确定有希望的目标来设计和/或重新利用有效药物。